Oral vasodilators for primary Raynaud's phenomenon - Wikidata - awgldk - TriplyDB

Oral vasodilators for primary Raynaud's phenomenon

Oral vasodilators for primary Raynaud's phenomenon

http://www.wikidata.org/entity/Q24202210

about

Raynaud's Phenomenon: A Brief Review of the Underlying Mechanisms Axillary Block-Induced Chemical Sympathectomy in the Setting of Digital Ischemia Latest advances in connective tissue disorders.Management of Raynaud's phenomenon and digital ischemia.Therapeutic implications from the pathogenesis of Raynaud's phenomenon.Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study.Evidence-based management of Raynaud's phenomenon.A Multicenter Study of the Validity and Reliability of Responses to Hand Cold Challenge as Measured by Laser Speckle Contrast Imaging and Thermography: Outcome Measures for Systemic Sclerosis-Related Raynaud's Phenomenon.

P2860

Q28067805-665FC6F9-8832-42FB-96A5-B3DE64EE5AB3 Q28817319-B27AD092-B3B9-46C6-8CAC-2EE0C66165C1 Q37058776-F8D683FB-C4AD-41BB-A1CD-F70F4E41A766 Q38071979-6CAEAA94-F216-4E90-9D0F-385C7B4927BB Q39090456-8DC80761-FEEE-486B-BA1B-301249509B8A Q47591657-FCFB6ED1-EAC2-42FF-BABD-6FAA2A3D15DD Q47803000-B2F081BE-DC2C-428D-A2BD-002A040003FF Q49860214-259C0581-3610-4552-BE8B-6C2D40B0A576

P2860

Oral vasodilators for primary Raynaud's phenomenon

http://www.wikidata.org/entity/Q24202210

description

2012 nî lūn-bûn

@nan

2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Oral vasodilators for primary Raynaud's phenomenon

@ast

Oral vasodilators for primary Raynaud's phenomenon

@en

Oral vasodilators for primary Raynaud's phenomenon

@en-gb

Oral vasodilators for primary Raynaud's phenomenon

@nl

type

label

Oral vasodilators for primary Raynaud's phenomenon

@ast

Oral vasodilators for primary Raynaud's phenomenon

@en

Oral vasodilators for primary Raynaud's phenomenon

@en-gb

Oral vasodilators for primary Raynaud's phenomenon

@nl

prefLabel

Oral vasodilators for primary Raynaud's phenomenon

@ast

Oral vasodilators for primary Raynaud's phenomenon

@en

Oral vasodilators for primary Raynaud's phenomenon

@en-gb

Oral vasodilators for primary Raynaud's phenomenon

@nl

P1433

Q24202210-A0808348-5410-4A0C-8BBE-5C96A0C837A0

P1476

Q24202210-227BEAB4-9F09-4DFD-A706-552EB89E6610

P2093

Q24202210-84D7B27F-50CB-46E6-90AC-46CFBAD1F460

Q24202210-DEC3D793-9BA1-4C5C-8F50-ACD9333415D8

P2860

Q24202210-01581B70-73A6-410F-96C3-1B13AF38DAF2

Q24202210-015BA7EF-CE77-4142-9538-003164246EC4

Q24202210-099027BE-413D-4A1C-9074-BE687A286EEC

Q24202210-09C7302D-E399-4968-992A-2A89ADF273F2

Q24202210-0E057F80-BA5B-4173-B5EA-9A60025FB86A

Q24202210-10E9B387-AB38-4A37-B587-939A7A4FB452

Q24202210-114D8EC4-2F00-4313-8675-DF3D01630119

Q24202210-12B5C67E-9959-499E-A50F-F94B69A77F21

Q24202210-1D445D0D-EA92-4600-8299-4913FAA8736E

Q24202210-258AC3BA-72AA-45BC-8007-B3F7C8496F01

P304

Q24202210-80DA6B9C-D177-4B6A-9EAB-E1E3F2480C46

P31

Q24202210-DBA93789-FC62-48A6-8B4F-70DDD332D850

Q24202210-d102222d-dfc3-4133-8308-a0d83ca2243f

P3181

Q24202210-7DD56D91-E371-49C0-8193-26B82F356104

P356

Q24202210-DA4ADF07-F808-4962-B675-5055450DD708

P433

Q24202210-EE75451A-86DD-4E1F-B3E3-FB3A30580395

P577

Q24202210-4669FA48-2E62-49E0-89D6-9F1DCEA485AB

P698

Q24202210-EAAA938D-B83F-4E05-860A-EE4A0A93E025

P932

Q24202210-BFE217DD-1627-40ED-9B51-8A0DAE95ECFC

P3181

P356

14651858.CD006687.PUB3

P1433

Cochrane Database of Systematic Reviews

P1476

Oral vasodilators for primary Raynaud's phenomenon

@en

P2093

Joanne R Morling

http://www.w3.org/2001/XMLSchema#string

Marlene Stewart

http://www.w3.org/2001/XMLSchema#string

P2860

Calcium channel blockers for primary Raynaud's Phenomenon

Oral vasodilators for primary Raynaud's phenomenon

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

Meta-analysis in clinical trials

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials

Meta-analyses involving cross-over trials: methodological issues

Effect of nitric-oxide-generating system on microcirculatory blood flow in skin of patients with severe Raynaud's syndrome: a randomised trial.

Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.

P304

CD006687

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2548122

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/14651858.CD006687.PUB3

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P577

2012-07-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22786498

http://www.w3.org/2001/XMLSchema#string

P932

6718219

http://www.w3.org/2001/XMLSchema#string